Oppenheimer Initiates Trillium Therapeutics With Outperform By: Benzinga via Benzinga May 15, 2015 at 09:54 AM EDT Analysts at Oppenheimer initiated coverage on Trillium Therapeutics Inc. (NASDAQ: TRIL) with a Outperform rating. The target price ... Read More >> Related Stocks: Trillium Therapeutic